VPM-1002 is under clinical development by Serum Institute of India and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase II drugs for Muscle Invasive Bladder Cancer (MIBC) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VPM-1002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VPM-1002 overview
Serum Institute of India overview
Serum Institute of India (Serum Institute) a subsidiary of Cyrus Poonawalla Group, is a biotechnology company specializing in the development and manufacture of vaccines and immuno-biologicals. The company’s main activities include the production of a wide range of vaccines for diseases such as polio, diphtheria, tetanus, pertussis, Hib, BCG, hepatitis B, measles, mumps, and rubella. Among its major products are life-saving vaccines that are accredited by the World Health Organization and used in national immunization programs across the globe. It markets the Oxford–AstraZeneca COVID-19 vaccine under the brand name Covishield in India. The company collaborates with international health organizations like WHO and PATH to enhance vaccine availability and efficacy. Its distribution network is extensive, ensuring that its vaccines reach a wide demographic. Serum Institute targets markets primarily in developing countries, aiming to address the healthcare needs of the most vulnerable populations. Serum Institute is headquartered in Pune, Maharashtra, India.
For a complete picture of VPM-1002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
